Posted by AGORACOM-AB
at 9:23 AM on Monday, October 18th, 2021
To understand the value proposition of TAAT, you first have to understand some recent massive trends in the Consumer Packaged Goods (CPG) space:
Non-alcoholic beer has grown to an $18bn USD market
The plant-based meat market is projected to hit $74bn USD By 2027
What they have in common is providing consumers of the original products with the exact same experience (taste, smell, etc.) without the negative parts of the original products.
TAAT has developed a nicotine-free and tobacco-free smoking experience known as TAAT™, which already launched in the USA. TAAT™ Beyond Tobacco™ cigarettes mimic those experiences without nicotine or tobacco.
Engineered to closely emulate the sensory components to provide the closest experience of smoking a tobacco cigarette – a product that tastes and smells just like tobacco – but without the nicotine.
October has seen a flurry of news for the company:
OCT 5: The company reported Q3 2021 Financial Results:
1. Gross revenue grew to an all-time high of $1,305,358 in Q3 2021, an increase of 1,956% YOY 2. Gross profit for Q3 2021 was $781,226 with a gross profit margin of 59.84% 3. Healthy balance sheet with $10,174,001 in working capital
OCT 6: TAAT Announced it Would Be Releasing A Branded Merchandise Line of Apparel and Accessories in Q1 2022
OCT 13: TAAT Announced A Follow-On Private Placement for CAD $10m
We sat down with CEO Setti Coscarella for a company update…
In this episode of the podcast, Dr. Steve Thayer and Dr. Reid Robison are joined for the second time by Dr. Paul Thielking, MD. He is a psychiatrist, zen practitioner, and Chief Scientific Officer at Novamind.
Chief Scientific Officer, Dr. Paul Thielking speaks with Amanda Siebert from The Dales Report on the potential of psychedelics for palliative care and the role of group therapy.
Chief Medical Officer, Dr. Reid Robison discusses Novamind being granted DEA licenses for psilocybin research and our new Psychedelic Palliative Care program with AGORACOM.
Dr. Reid Robison opened the PSYCH Investor Summit with a keynote address presenting Novamind’s positioning and the rise and rollout of psychedelic medicine.
We are pleased to announce we have been granted Schedule 1 licenses (the “DEA Licenses”) from the U.S. Drug Enforcement Agency (DEA) for Dr. Reid Robison, Chief Medical Officer, and Dr. Paul Thielking, Chief Scientific Officer. The DEA Licenses are required for research sites planning to host clinical trials for psilocybin, enabling principal investigators to store and administer this controlled substance.
“Obtaining the DEA Licenses is a critical step towards hosting clinical trials for psilocybin-assisted psychotherapy,” commented Dr. Robison. “We’re proud of our clinical research organization’s track record investigating innovative solutions for central nervous system conditions. This milestone reflects our expertise and enables us to continue on our mission to create breakthroughs in mental health treatment.”
Psilocybin has shown significant positive outcomes for people with major depressive disorder¹ and for reducing anxiety and depression in people with life-threatening cancer.² As of today, there are over 50 clinical studies actively examining the use of psilocybin, as listed on www.clinicaltrials.gov.
“The DEA Licenses are timely,” said Dr. Thielking, who last week launched Psychedelic Palliative Care by Novamind, a first of its kind program to support the mental health of patients and families struggling with serious illness. “We anticipate that this progress will accelerate the approval process for us to become a research site for additional psychedelic clinical studies in the future.”
Time magazine writes how the burnout, trauma and stress caused by the COVID-19 pandemic is opening the door to accelerated psychedelic research. “It’s no coincidence that psychedelics are entering the conversation at the moment we most sorely need new ideas in mental health care. The world is experiencing mass trauma from COVID-19.” It’s especially true with frontline workers. The stats are alarming. The need has never been more apparent. It’s why we launched our Frontline Ketamine-Assisted Psychotherapy treatment program earlier this year. We’re providing healthcare workers with critical mental healthcare. You can learn more about the program here.
Therapeutic Goods Administration (TGA) in Australia is currently evaluating a proposal to reschedule two prominent psychedelics into a less restrictive classification. Mind Medicine Australia submitted the proposal to the government and “has the support of world leading experts in psychedelic research.” Novamind Chief Medical Officer, Dr. Reid Robison, will be presenting at the Mind Medicine Australia summit in November. Get your tickets here.
Could psychedelics follow the same path of cannabis toward legalization and regulation for medical purposes? It’s a question Luis Millán asks for National Magazine. “Despite the legal uncertainty, business is hopeful. Some stock market speculators believe psychedelics will follow in the footsteps of the cannabis industry and become the next billion-dollar business.”
Posted by AGORACOM-JC
at 4:12 PM on Wednesday, October 13th, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
Q3 Highlights:
Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
Record 9 months revenues at $10.2 million , up 94%
2 Group Purchasing Organizations listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products
The 2 multi-year product listings commenced on October 1, 2021
The GPOs together represent more than 700 hospitals and healthcare facilities across 5 provinces including Ontario
The agreement above supports $30M annual revenue target From blood thinner product alone!
As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.
Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss self-compassion, why it is so hard (but so important) to forgive, and how to detox from judgement.
Novamind’s Chief Medical Officer opened the Summit with a keynote drawing on his career as a pioneering psychiatrist and researcher in ketamine-assisted psychotherapy. Check back next week for footage of his presentation.
We are pleased to launch Psychedelic Palliative Care by Novamind (the “Palliative Program”) at its recently opened clinic and research site in Murray, Utah.
Among the first-of-its-kind, the Palliative Program combines psychedelic medicine with psychotherapy, workshops, multi-day immersive retreats and group support for palliative care patients and families who are coping with chronic and serious illness.
“Patients receiving palliative care have higher rates of depression than the general population. Unfortunately, standard anti-depression and anti-anxiety treatments do not work for everyone, can cause side effects, and can take up to eight weeks to work,” explained Dr. Paul Thielking, Chief Scientific Officer (CSO) of Novamind. “Due to psychedelic medicine’s generally low side effect burden and fast-acting nature, it shows promise for patients who are physically ill and might have limited life expectancies.”
Through Novamind’s clinical research division, the Palliative Program will host studies to investigate the use of psychedelic medicine including ketamine and establish the infrastructure for future clinical studies examining psilocybin. This work will build on notable studies from New York University and Johns Hopkins University, which demonstrated psilocybin’s significant immediate and sustained improvements in anxiety and depression symptoms in cancer patients.
Prior to his role as Novamind’s CSO, Dr. Thielking developed ketamine-assisted treatment protocols for cancer patients experiencing depression at the University of Utah Huntsman Cancer Institute (HCI). He also pioneered an ongoing HCI study examining the feasibility of group-administered psilocybin-assisted psychotherapy for cancer patients experiencing depression. Dr. Thielking leads the Palliative Program’s multidisciplinary team of mental health professionals specialized in palliative care and psychedelic-assisted psychotherapy.
“Our healthcare system struggles to support the millions of Americans dealing with emotional, spiritual and psychological suffering associated with chronic or serious illness,” noted Dr. Thielking. “Psychedelic Palliative Care by Novamind is designed to address this need, bringing together fast-acting medicine, innovative treatment options and therapeutic expertise in a safe, nurturing environment.”
We announced our participation in two upcoming virtual investor conferences on Wednesday, October 13, 2021.
Novamind’s CEO and Director, Yaron Conforti, will present our progress towards expanding access to psychedelic medicine in the U.S., including the recent opening of our sixth clinic and the newly launched Psychedelic Palliative Care program.
Virtual LD Micro Main Event XIV Date: October 13, 2021 Time: 10:30 AM to 11:00 AM EST Register and watch live here: me21.mysequire.com
In a collaboration with DoubleBlind magazine, Shelby Hartman and Madison Margolin explore how professional and economic systems are changing as the psychedelic revolution continues to grow. It’s not just about growth, though, but also the way we work. “What psychedelics offer is an invitation to look at professional and economic systems more, well, psychedelically.”
Covering Rick Doblin’s talk at the 2021 Annual Psychiatric Times World CME Conference, Leah Kuntz writes about what other conditions MDMA could treat including “depression, alcohol dependence, obsessive compulsive disorder, and even demoralization in AIDS survivors.” We look forward to further research on MDMA and will work to create treatment protocols for an array of mental health conditions, similar to our work with ketamine.
“According to estimates by the World Health Organization, about 300 million people worldwide live with depression.” It’s a stat that illuminates why there is so much urgency to bring psychedelic-assisted therapies to the world. We want to make a difference, to improve the quality of life for people suffering from depression and other mental health conditions, regardless of the psychedelic being used to bring about that lasting change. From Chief Medical Officer, Dr. Reid Robison: “I’m always touched by stories of hope and healing that come from witnessing the psychedelic modalities in action.”
Posted by AGORACOM-JC
at 4:32 PM on Thursday, October 7th, 2021
FOBI is a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement in the brick and mortar space. From that core technology they have built a technology stack on top of it that is second to none.
They have created multiple successful applications that, for the purposes of this interview, includes their venue management platform that has been deployed at multiple NCAA tournaments, a recent MGM Resorts Championship PGA Event in Las Vega and most recently signed a deal to bring their venue management solutions to the Canadian Hockey League, the world’s largest development hockey league with 9 Million Fan Visits in 2019.
How important is this acquisition? CEO Rob Anson says it best:
“This represents a key achievement for Fobi and its shareholders. This acquisition of PassWallet positions Fobi as an up and coming leader in the digital wallet space. The company has made great strides this year and this key strategic development positions us extremely well, enabling us to leverage and monetize on a standard ARPU model (average revenue per user). With over 6 million downloads currently, management believes that by leveraging our artificial intelligence and data solutions as well as the integration of Fobi’s marketing power together with the global wallet pass growth rates, that this number will grow significantly in 2022. Coupled with further untapped opportunity and an addressable market of over 150 countries that are currently not serviced by Google Pay, management anticipates that with this acquisition Fobi is now well positioned to expand into the FinTech space.”
Sit back and watch this powerful interview with CEO Rob Anson AND… Fobi SVP of Corporate Strategy & Corporate Development Richard Lee.
Posted by AGORACOM-JC
at 10:01 AM on Wednesday, October 6th, 2021
12 months ago investors couldn’t be blamed if they found it hard to grasp the genius and foresight of Liquid Avatar $LQID $LQAVF ….. the easiest way to describe the company was as a blockchain platform allowing people to manage & profit from their digital identity, which became a real need once global laws started being enacted to prevent the likes of Facebook from every abusing our private information again.
Moreover, the platform also provides both businesses and governments the ability to easily integrate digital wallets and digital identity solutions through its Liquid Avatar platform (www.liquidavatar.com).
It sounded great … and definitely sounded like something you could see starting to happen 3-4 years into the future … but then the signs started showing up that painted an accelerating picture that would put LQID at the forefront of digital identity.
1. In March of this year, Google validated the $LQID business model with this stunning announcement:
Google believes these types of tracking methods don’t “meet rising consumer expectations for privacy, nor will they stand up to rapidly evolving regulatory restrictions, and therefore aren’t a sustainable long term investment.”
Google is experimenting with tools in its Privacy Sandbox that are designed to allow advertising to continue to work on the web but in a less privacy-encroaching way.
“Keeping the internet open and accessible for everyone requires all of us to do more to protect privacy — and that means an end to not only third-party cookies, but also any technology used for tracking individual people as they browse the web,” David Temkin, Google’s director of product management for ads privacy and trust,
What is the potential outcome of this major shift by Google?
“Google’s decision could upend the ad industry, which has relied on these types of tracking tools”
With this news, the data privacy and monetization game is underway and LQID sitting in a great position within the industry and the dominant position within the small cap world.
BUT THAT’S NOT ALL
2. In May of this year, The Ontario government released its digital identity strategy outlining ways in which it plans to harness the potential of the digital economy and better utilize data. Included in the plan are tangible commitments.
Then came the news all Liquid Avatar investors were waiting for:
the introduction of a new government-issued digital ID that lets people prove who they are both online and in person.
These 2 announcements out of Google and the Ontario Government officially put both business and government in the digital identity and credentials game. There is no looking back.
ENTER LIQUID AVATAR – WORKING WITH ONTARIO GOVERNMENT
Enter $LQID whose Liquid Avatar Verifiable Credentials Ecosystem (LAVCE) is being built to support all participants in a digital credential ecosystem, including the Holder, Issuer and Verifier, using state-of-the-art blockchain and open standards technologies . More than just a good idea, $LQID issued a press release announcing the following:
“Ontario is one of the first jurisdictions in North America to announce that it will issue and enable digital credentials – and it has been a great experience working with the government on this both directly and through our role in membership organizations like the Trust Over IP Foundation”
AND
“Liquid Avatar Technologies has been a part of the ongoing consultations around the province’s plan to introduce a digital identification credential by the end of 2021”
ENTER LIQUID AVATAR – OUT OF DEVELOPMENT AND INTO COMMERCIALIZATION WITH 8,000 CONVENIENCE STORES
This morning $LQID released major news on the commercialization side whose title speaks for itself:
According to CEO Lucatch, this announcement represents a major inflection point as it signals a shift from development to commercialization, with many more potential deals in discussion.
LQID IS THE LEADING SMALL CAP COMPANY IN MASSIVE PARADIGM SHIFT TOWARD DIGITAL IDENTITY, PRIVACY AND MONETIZATION
Make no mistake about it. This is a simply massive paradigm shift and $LQID isn’t going to tackle this on its own. The Company is a voting and steering committee member of the Trust over IP Foundation, founding and steering committee member of Cardea, a Linux Foundation Public Health project, member of the Good Health Pass collaborative, ID2020, DIACC, The Linux Foundation and a founding member of the Lumedic Exchange.
Suddenly it is getting easy to see the genius of Liquid Avatar.
Watch this great interview with CEO David Lucatch.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss fear, the difference between pain vs. suffering, and the value of struggle in life.
We are pleased to announce the opening of our sixth integrative psychiatry clinic. The clinic is in Murray, Utah (the “Murray Clinic”).
The Murray Clinic also serves as Novamind’s third clinical research site, further strengthening the Company’s capabilities for serving drug developers via multiple sites and access to a large patient population. The Company anticipates 65,000 visits to its clinics this year.
“Bringing cost-effective and innovative psychedelic therapies to market requires a large base of diverse candidates and the expertise to safely and effectively run complex clinical trials in the right environment,” explained Yaron Conforti, CEO and Director. “We continue to build on our model’s proven track record through the expansion of our clinics and research sites, and we expect to scale this unique operating model into additional states in the near term.”
The Murray Clinic is the latest in Novamind’s ongoing clinic expansion, with two additional clinics slated to open in Utah by the end of 2021. The Salt Lake City location is scheduled to open in October, while the Park City location will open in November to accommodate the construction of the Company’s new flagship clinic design.
Learn more about Novamind’s clinical research division here.
The evidence continues to grow in support of psychedelic medicine. In a piece for the Independent, Jonathan Sabbagh writes about how psychedelics, and ketamine-assisted psychotherapy in particular, changed his life. “For the first time, I understood the truth. My burnout wasn’t an end in itself. It was a symptom of a previously undiagnosed severe case of post-traumatic stress disorder.”
Axios breaks down why psychedelics matter, where they stand and what to watch for in the future. “Scientific studies of psychedelic therapies may be entering a new, broader phase thanks to more interest and funding from federal governments.” We will continue to research psychedelics and other innovative therapies at Cedar Clinical Research. CCR’s research sites are co-located with Novamind’s Cedar Psychiatry clinics allowing for large client population recruitment and providing clients access to innovative research stage treatments. And just this last week, we announced the opening of a new research site and clinic.
Posted by AGORACOM-Eric
at 4:55 PM on Thursday, September 30th, 2021
MVMD Takes Existing Vaccines and Drugs – And Delivers Them Better. Both Into The Body and By Transportation To The World. Way Better.
For the purposes of introducing you to Mountain Valley MD (MVMD), we’ll use vaccines as an example given the state of the world since COVID-19 arrived. Specifically, we’ve all heard more about vaccines in 12 months than we have in the last 12 years. One thing we all know about vaccines is that vaccination is the safest way to protect people against infectious diseases.
BUT
One thing we don’t know or understand about vaccinations is that they are only as good as:
1. The global physical delivery system that actually gets them from the manufacturer to the hands of nurse who injects the vaccine;
2. The delivery system into your body (i.e. injection)
If either parts of these delivery systems are weak, or even fail, a vaccine loses some or even all of its potency – and that’s not good. This is where MVMD comes in. They don’t make the vaccines, drugs or pharmaceuticals.
What they do is make their delivery better. Their physical delivery until their ultimate delivery into your body – and that is very good. By doing so, they help save lives and they help manufacturers be more profitable – and that is very good for humanity and shareholders.
A “magic bullet” is of little use without a “magic gun” – Mountain Valley MD Is The Magic Gun.
Check out these Trials & Research MVMD is accomplishing with their Vaccine technology to improve our lives:
* Expanding Oncology Work for BreastCancer using Quicksol™ technology applications
* Farm Animal Trials Using Solubilized Ivermectin
* Discovering Immediate Demand for Generic Ivermectin Uses
The latest news Involves utilizing their vaccine technology to address & develop products for the Medical Sleep Market in the U.S. strictly using cannibinoids.
Sit back and enjoy the great interview with President & CEO Dennis Hancock as he explains the developing relationship with Red White & Bloom to create products for the US sleep market.
Posted by AGORACOM-JC
at 12:17 PM on Thursday, September 30th, 2021
HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing high value-added silicon products that are sought after by battery and electric vehicle manufacturers – but nobody has yet delivered – until now.
If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following:
How powerful is this Revolutionary & Breakthrough Green Hydrogen? Try “SCALABLE WITH NO LIMITS”
“EBH2 is scalable with no limits. It can power a small domestic generator up to ships, factories, buildings, cryptocurrency mines with high energy consumption and even cities.”
Independent validation of the technology is expected to be complete over the next 60 days. If successful, HPQ proposes to bundle the energy production capability of EBH2 systems with its silicon production to further reduce the environmental footprint of its developing high purity silicon, nano powders, and other Renewable Energy products. Moreover, if successful, EBH2 would provide HPQ with “power plant” capabilities that would allow it to produce its products anywhere on the planet.
If that wasn’t enough HPQ added the following:
“all the while opening up new, and massive addressable markets for a system that can produce cheaply green hydrogen, on demand …. The Agreement establishes the terms of the creation of a new Joint venture Company (“NEWCO”) owned by HPQ and EBH2 that will market, sell and service EBH2 systems and products in North America (Canada, Mexico, and the United States). …. units could readily replace solar panels or standby generators for homeowners.”
Watch this great interview with $HPQ CEO Bernard Tourillon to get the full picture on next steps!
Posted by AGORACOM-JC
at 8:53 AM on Thursday, September 30th, 2021
Earlier today Novamind Inc. (NM : CSE) (NVMDF: OTCQB) (HN2: FSE) opened its sixth integrative psychiatry clinic. The “Murray Clinic” also serves as Novamind’s third clinical research site, further strengthening the Company’s capabilities for serving drug developers via multiple sites and access to a large patient population.
The Company anticipates 65,000 visits to its clinics this year.
Yaron Conforti, CEO and Director, “Bringing cost-effective and innovative psychedelic therapies to market requires a large base of diverse candidates and the expertise to safely and effectively run complex clinical trials in the right environment. We continue to build on our model’s proven track record through the expansion of our clinics and research sites, and we expect to scale this unique operating model into additional states in the near term.”
Sit back, relax and watch this powerful interview with Yaron Conforti, CEO and Director of Novamind.
